Private Capital Advisors Inc. Has $1.38 Million Stake in Immunome, Inc. $IMNM

Private Capital Advisors Inc. cut its position in shares of Immunome, Inc. (NASDAQ:IMNM) by 37.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 118,046 shares of the company’s stock after selling 71,798 shares during the quarter. Private Capital Advisors Inc. owned about 0.13% of Immunome worth $1,382,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of IMNM. Assetmark Inc. bought a new stake in Immunome during the third quarter valued at $39,000. BNP Paribas Financial Markets grew its stake in Immunome by 81.8% during the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock worth $60,000 after purchasing an additional 2,909 shares during the period. Tower Research Capital LLC TRC increased its holdings in Immunome by 121.2% in the second quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock worth $65,000 after purchasing an additional 3,802 shares in the last quarter. BIT Capital GmbH acquired a new position in Immunome in the third quarter valued at approximately $69,000. Finally, Brighton Jones LLC acquired a new position in Immunome in the second quarter valued at approximately $98,000. Institutional investors own 44.58% of the company’s stock.

Immunome Price Performance

IMNM opened at $22.14 on Thursday. Immunome, Inc. has a fifty-two week low of $5.15 and a fifty-two week high of $27.65. The firm has a market capitalization of $2.44 billion, a PE ratio of -7.51 and a beta of 2.32. The company’s 50-day moving average is $22.73 and its 200 day moving average is $17.15.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. HC Wainwright initiated coverage on shares of Immunome in a research report on Thursday, February 12th. They set a “buy” rating and a $40.00 price objective for the company. Leerink Partners set a $40.00 price target on shares of Immunome in a report on Monday, December 15th. Wedbush reiterated an “outperform” rating and set a $31.00 price objective on shares of Immunome in a report on Thursday, January 15th. Stephens raised their target price on Immunome from $25.00 to $33.00 and gave the company an “overweight” rating in a research note on Monday, November 17th. Finally, Evercore increased their price target on Immunome from $18.00 to $40.00 and gave the stock an “outperform” rating in a report on Tuesday, December 16th. Eleven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Immunome presently has an average rating of “Moderate Buy” and a consensus price target of $31.75.

Insider Activity

In related news, Director Isaac Barchas sold 383,200 shares of Immunome stock in a transaction that occurred on Monday, December 22nd. The stock was sold at an average price of $21.74, for a total transaction of $8,330,768.00. Following the transaction, the director owned 2,031,181 shares of the company’s stock, valued at $44,157,874.94. The trade was a 15.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Clay B. Siegall acquired 46,511 shares of the company’s stock in a transaction on Thursday, December 18th. The shares were bought at an average price of $21.50 per share, for a total transaction of $999,986.50. Following the completion of the purchase, the chief executive officer owned 853,247 shares in the company, valued at approximately $18,344,810.50. This represents a 5.77% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased 68,518 shares of company stock worth $1,453,958 over the last 90 days. 7.69% of the stock is currently owned by corporate insiders.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.